Ascendis Pharma A/S (ASND) Competitors

BioNTech (NASDAQ:BNTX) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, community ranking, dividends and institutional ownership.

Does the MarketBeat Community favor BNTX or ASND?

Ascendis Pharma A/S received 301 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 66.62% of users gave Ascendis Pharma A/S an outperform vote while only 46.05% of users gave BioNTech an outperform vote.

Company	Underperform	Outperform
BioNTech	Outperform Votes 140 46.05%	Underperform Votes 164 53.95%
Ascendis Pharma A/S	Outperform Votes 441 66.62%	Underperform Votes 221 33.38%

Is BNTX or ASND more profitable?

BioNTech has a net margin of -15.16% compared to Ascendis Pharma A/S's net margin of -130.33%. Ascendis Pharma A/S's return on equity of 0.00% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-15.16%	-2.35%	-2.05%
Ascendis Pharma A/S	-130.33%	N/A	-48.77%

Which has more volatility & risk, BNTX or ASND?

BioNTech has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.

Do analysts recommend BNTX or ASND?

BioNTech presently has a consensus target price of $142.72, indicating a potential upside of 15.31%. Ascendis Pharma A/S has a consensus target price of $191.57, indicating a potential upside of 46.62%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93

Which has preferable valuation and earnings, BNTX or ASND?

BioNTech has higher revenue and earnings than Ascendis Pharma A/S. BioNTech is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$4.13B	7.18	$1.01B	-$2.10	-58.94
Ascendis Pharma A/S	$288.08M	27.53	-$521.07M	-$8.08	-16.17

Does the media prefer BNTX or ASND?

In the previous week, BioNTech and BioNTech both had 10 articles in the media. BioNTech's average media sentiment score of 0.94 beat Ascendis Pharma A/S's score of 0.91 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals have more ownership in BNTX or ASND?

15.5% of BioNTech shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

BioNTech and Ascendis Pharma A/S tied by winning 8 of the 16 factors compared between the two stocks.